– USA, CA – Intersect ENT, Inc. (NASDAQ: XENT), a global ear, nose, and throat medical technology leader dedicated to transforming patient care, today announced the appointment of Elisabeth Sandoval-Little to its Board of Directors, effective on March 31, 2021, replacing Anthony Vernon who has resigned from the Board.
“We are pleased to welcome Elisabeth to the Intersect Board,” said CEO, Thomas West. “Elisabeth is an accomplished commercial executive with more than 30 years of experience in the biopharmaceutical and specialty therapeutics industries at both large market-leaders and development-stage companies. She has worked with products at all stages of the product lifecycle and her strong knowledge of the interplay between product and claims development and commercialization will be a great fit with Intersect ENT’s strategy and growth aspirations.”
About Elisabeth Sandoval-Little
Elisabeth Sandoval-Little currently serves as a consultant to the pharmaceutical industry and is a member of the board of directors of Satsuma Pharmaceuticals, Inc. and Vyne Therapeutics, Inc. She is also on the Board of privately-held Alastin Skincare. Ms. Sandoval-Little previously served as the Chief Commercial Officer and Executive Vice President of Corporate Strategy at Alder Biopharmaceuticals. She was Chief Commercial Officer for Kythera Biopharmaceuticals and spent 23 years at Allergan in a variety of commercial leadership roles of increasing responsibility. Ms. Sandoval-Little began her career in research and development at Johnson & Johnson’s Ethicon division.
“I am delighted to be joining Intersect ENT,” said Ms. Sandoval-Little. “With an established commercial presence, an expanding product base, and a strong clinical program, this is an exciting time for the Company. I look forward to contributing to its future growth.”
Ms. Sandoval-Little holds an M.B.A. from Pepperdine University and a B.S. in Biology from the University of California, Irvine.
About Intersect ENT
Intersect ENT is a global ear, nose, and throat medical technology leader dedicated to transforming patient care. The Company’s steroid releasing implants are designed to provide mechanical spacing and deliver targeted therapy to the site of disease. Also, Intersect ENT is continuing to expand its portfolio of products based on the Company’s unique localized steroid releasing technology and is committed to broadening patient access to less invasive and more cost-effective care. In October 2020, Intersect ENT acquired Fiagon AG Medical Technologies, a global leader in electromagnetic surgical navigation solutions with an expansive portfolio of ENT product offerings, including the VENSURE sinus balloon, that complement the Company’s PROPEL and SINUVA sinus implants and extend its geographic reach.
For more information: https://www.intersectent.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.